0000000000007443

AUTHOR

Gabriele Pozzato

showing 9 related works from this author

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

2015

Sara Capolla,1 Chiara Garrovo,2 Sonia Zorzet,1 Andrea Lorenzon,3 Enrico Rampazzo,4 Ruben Spretz,5 Gabriele Pozzato,6 Luis Núñez,7 Claudio Tripodo,8 Paolo Macor,1,9 Stefania Biffi2 1Department of Life Sciences, University of Trieste, 2Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, 3Animal Care Unit, Cluster in Biomedicine (CBM scrl), Trieste, Italy; 4Department of Chemistry “G. Ciamician”, University of Bologna, Bologna, Italy; 5LNK Chemsolutions LLC, Lincoln, NE, USA; 6Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 7Bio-Target, Inc., University of C…

Medicine (General)Active targeting; Optical imaging; Tumor accumulation; Animals; Antigens CD20; Cell Line Tumor; Humans; Leukemia B-Cell; Mice; Molecular Imaging; Nanoparticles; Polymers; Drug Delivery Systems; Bioengineering; Biophysics; Biomaterials; Drug Discovery3003 Pharmaceutical Science; Organic ChemistryTumor accumulationPolymersPharmaceutical SciencePharmacologyOptical imagingMiceDrug Delivery SystemsNanoparticleInternational Journal of NanomedicineDrug DiscoveryPolymerOriginal ResearchActive targeting; Optical imaging; Tumor accumulation; Animals; Antigens CD20; Cell Line Tumor; Humans; Leukemia B-Cell; Mice; Molecular Imaging; Nanoparticles; Polymers; Drug Delivery Systems; Biophysics; Bioengineering; Biomaterials; Organic Chemistry; Drug Discovery3003 Pharmaceutical ScienceTumorLeukemiaActive targetingtumor accumulationGeneral MedicineMolecular ImagingDrug deliverySystemic administrationPreclinical imagingHumanactive targetingMaterials scienceBiophysicsBioengineeringCell LineBiomaterialsoptical imagingR5-920In vivoCell Line TumormedicineLeukemia B-CellDistribution (pharmacology)AnimalsHumansCD20AntigensAnimalDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryB-CellCancermedicine.diseaseAntigens CD20BiomaterialTargeted drug deliveryBiophysicNanoparticlesMolecular imagingDrug Delivery System
researchProduct

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells

2017

The limited efficacy of available treatments for hepatocellular carcinoma (HCC) requires the development of novel therapeutic approaches. We synthesized a novel cationic polymer based on α,β-poly-(N-2-hydroxyethyl)-D,L-aspartamide (PHEA) for drug delivery to HCC cells. The copolymer was synthesized by subsequent derivatization of PHEA with diethylene triamine (DETA) and with a polyethylene glycol (PEG) derivative bearing galactose (GAL) molecules, obtaining the cationic derivative PHEA-DETA-PEG-GAL. PHEA-DETA-PEG-GAL has suitable chemical-physical characteristics for a potential systemic use and can effectively deliver a siRNA (siE2F1) targeted against the transcription factor E2F1, a gen…

Polyplexes HCC siRNA E2F1 PHEA-DETA-PEG-GALCarcinoma HepatocellularPolymersPharmaceutical ScienceE2F1; HCC; PHEA-DETA-PEG-GAL; Polyplexes; siRNA.02 engineering and technologyPolyethylene glycol03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumorPEG ratiomedicineHumansE2F1Gene silencingGene SilencingRNA Small InterferingHCCReceptorCell growthChemistryLiver NeoplasmssiRNA.021001 nanoscience & nanotechnologymedicine.diseaseMolecular biologyPHEA-DETA-PEG-GALPolyplexeE2F1030220 oncology & carcinogenesisHepatocellular carcinomasiRNADrug deliveryCancer researchPeptides0210 nano-technologyE2F1 Transcription FactorPolyplexes
researchProduct

New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles

2012

Abstract Abstract 158 B-cell disorders show highly variable clinical courses, ranging between indolent diseases like the chronic lymphocytic leukemia (CLL) and highly aggressive lymphoproliferative disorders like Burkitt Lymphoma. The treatments of these disorders have been characterized by the development of new approaches, including dose-intensive chemotherapy regimens and immunotherapy via monoclonal antibodies (Ab). Despite the promising survival rates, these multi-agent treatments are flawed by a high degree of toxicity and a significant fraction of patients do not respond. The use of core shell nanoparticles design with specific Ab-coating represents a new strategy to target only tumo…

CD20biologyChlorambucilbusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyIntraperitoneal injectionCell BiologyHematologyImmunotherapyPharmacologymedicine.diseaseBiochemistryLeukemiamedicine.anatomical_structureImmunologyCancer cellmedicinebiology.proteinbusinessB cellmedicine.drugBlood
researchProduct

Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis

2019

Abstract Despite the advances in the treatment of rheumatoid arthritis (RA) achieved in the last few years, several patients are diagnosed late, do not respond to or have to stop therapy because of inefficacy and/or toxicity, leaving still a huge unmet need. Tissue-specific strategies have the potential to address some of these issues. The aim of the study is the development of a safe nanotechnology approach for tissue-specific delivery of drugs and diagnostic probes. CD34 + endothelial precursors were addressed in inflamed synovium using targeted biodegradable nanoparticles (tBNPs). These nanostructures were made of poly-lactic acid, poly-caprolactone, and PEG and then coated with a synovi…

musculoskeletal diseases0301 basic medicineBiodistributionCD34; +; cells; Neoangiogenesis; Rheumatoid arthritis; Targeted nanoparticles; Targeted therapymedicine.medical_treatmentTargeted nanoparticlesImmunologyArthritisInflammation+Targeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and AllergyProgenitor cellRheumatoid arthritisRheumatoid arthritiTargeted nanoparticleNeoangiogenesis030203 arthritis & rheumatologybusiness.industrycellmedicine.diseaseNeoangiogenesi030104 developmental biologyRheumatoid arthritisToxicityCancer researchcellsMethotrexateCD34medicine.symptombusinessmedicine.drug
researchProduct

Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs

2015

Nucleic acid based drugs (NADBs) are short DNA/RNA molecules that include among others, antisense oligonucleotides, aptamers, small interfering RNAs and micro-interfering RNAs. Despite the different mechanisms of actions, NABDs have the ability to combat the effects of pathological gene expression in many experimental systems. Thus, nowadays, NABDs are considered to have a great therapeutic potential, possibly superior to that of available drugs. Unfortunately, however, the lack of effective delivery systems limits the practical use of NABDs. Due to their hydrophilic nature, NABDs cannot efficiently cross cellular membrane; in addition, they are subjected to fast degradation by cellular and…

Cellular membranePolymersAntisense oligonucleotides aptamers carbon nanotubes exososomes liposomes miRNA polymers siRNAAptamerClinical BiochemistryNanotechnologyAnimals; Humans; Lipids; Nanoparticles; Nanotubes Carbon; Nucleic Acids; Polymers; Drug Delivery SystemsBiologyNanoparticleDrug Delivery SystemsNucleic AcidsAnimalsHumansAvailable drugsPolymerPharmacologyNanotubesNucleic AcidAnimalNanotubes CarbonCarbon chemistryRNALipidLipidsCarbonSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAntisense oligonucleotidesNucleic acidNanoparticlesHuman
researchProduct

Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer

2021

Given the lack of effective treatments for Hepatocellular carcinoma (HCC), the development of novel therapeutic approaches is very urgent. Here, siRNAs were delivered to HCC cells by a synthetic polymer containing α,β-poly-(N-2-hydroxyethyl)-D,L-aspartamide-(PHEA) derivatized with diethylene triamine (DETA) and bearing in the side chain galactose (GAL) linked via a polyethylene glycol (PEG) to obtain (PHEA-DETA-PEG-GAL, PDPG). The GAL residue allows the targeting to the asialo-glycoprotein receptor (ASGPR), overexpressed in HCC cells compared to normal hepatocytes. Uptake studies performed using a model siRNA or a siRNA targeted against the enhanced green fluorescence protein, demonstrated …

Small interfering RNACarcinoma HepatocellularPolymersHepatocellular carcinomaCellASGPR targeted delivery; E2F1; Eukaryotic elongation Factor 1A; Hepatocellular carcinoma; siRNAPharmaceutical Science02 engineering and technologyEukaryotic elongation Factor 1AMice03 medical and health sciencesIn vivomedicineAnimalsE2F1RNA Small InterferingReceptor030304 developmental biology0303 health sciencesChemistryLiver NeoplasmsASGPR targeted deliveryGalactose021001 nanoscience & nanotechnologymedicine.diseasedigestive system diseasesEukaryotic translation elongation factor 1 alpha 1In vitromedicine.anatomical_structureE2F1Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomasiRNACancer research0210 nano-technology
researchProduct

CD49d Expression Identifies a Chronic Lymphocytic Leukemia (CLL) Subset with High Levels of Circulating CD34 +Cells Co-Expressing Endothelial Cell Ma…

2009

Abstract Abstract 2329 Poster Board II-306 Introduction: In chronic lymphocytic leukemia (CLL), CD49d, often in association with CD38, has been shown to mark a disease subset with poor prognosis. Functionally, both molecules act as counter-receptors for surface structures (i.e. VCAM-1/CD106 and CD31) usually expressed by the endothelial/stromal component of tumor micro-environment. We have recently identified a micro-environmental circuitry which involves CD38 triggering, and eventually determines an enrichment of the VCAM-1/CD106-expressing endothelial component detected in the context of CLL infiltrates found in bone marrow biopsies. Data was also provided that CD49d/VCAM-1 interactions a…

education.field_of_studymedicine.diagnostic_testChronic lymphocytic leukemiaImmunologyPopulationCD34Context (language use)Cell BiologyHematologyBiologyCD38medicine.diseaseBiochemistryMolecular biologyFlow cytometryEndothelial stem cellmedicine.anatomical_structurehemic and lymphatic diseasesImmunologymedicineBone marroweducationBlood
researchProduct

A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles

2015

Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegrada…

0301 basic medicineChronic lymphocytic leukemiaxenograft modelchronic lymphocytic leukemia; immune targeted nanoparticles; treatment; xenograft model; Electrical and Electronic Engineering; Materials Science (all)Nanotechnology03 medical and health sciencesTherapeutic approach0302 clinical medicinehemic and lymphatic diseasesmedicineGeneral Materials ScienceElectrical and Electronic EngineeringCytotoxicityCD20immune targeted nanoparticletreatmentChlorambucilbiologybusiness.industryTherapeutic effectHydroxychloroquineCondensed Matter Physicsmedicine.diseaseAtomic and Molecular Physics and OpticsLeukemia030104 developmental biology030220 oncology & carcinogenesisimmune targeted nanoparticlesCancer researchbiology.proteinchronic lymphocytic leukemiaMaterials Science (all)businessmedicine.drugNano Research
researchProduct